Literature DB >> 23538787

Synthesis of the IGF-II-like hormone vesiculin using regioselective formation of disulfide bonds.

Geoffrey M Williams1, Garth J S Cooper, Kathryn Lee, Lynda Whiting, Margaret A Brimble.   

Abstract

Diabetes mellitus, characterised by hyperglycemia and altered β-cell function, is an increasingly common disorder affecting millions of individuals world-wide. While therapeutic regimens exist to manage the condition, diabetic individuals remain prone to complications that are detrimental to both their length and quality of life. An improved understanding of the disease which may then enable development of new treatments is therefore a desirable goal. Vesiculin, a novel IGF-II-like protein was recently isolated from the secretory granules of murine β-cells, and preliminary studies indicate it is capable of signalling via the insulin receptor (IR)/insulin-like growth factor receptor 1(IGF1R) family giving it the potential to elicit both metabolic and mitogenic responses in the beta-cell. In order to facilitate further studies on this new member of the insulin-family of hormones, we undertook a chemical synthesis of the protein using regioselective disulfide bond formation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23538787     DOI: 10.1039/c3ob40322j

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  2 in total

1.  Synthesis and Characterization of an A6-A11 Methylene Thioacetal Human Insulin Analogue with Enhanced Stability.

Authors:  Nan Zheng; Prasoona Karra; Michael A VandenBerg; Jin Hwan Kim; Matthew J Webber; William L Holland; Danny Hung-Chieh Chou
Journal:  J Med Chem       Date:  2019-12-13       Impact factor: 7.446

2.  Vesiculin derived from IGF-II drives increased islet cell mass in a mouse model of pre-diabetes.

Authors:  Kate L Lee; Jacqueline F Aitken; Xun Li; Kirsten Montgomery; Huai-L Hsu; Geoffrey M Williams; Margaret A Brimble; Garth J S Cooper
Journal:  Islets       Date:  2021-10-09       Impact factor: 2.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.